BioVaxys Technology Corp. Announces Revocation of Management Cease Trade Order and Debt Settlement
Vancouver, BC, April 10, 2025 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) is pleased to announce that the management cease trade order (MCTO) issued by the British Columbia Securities Commission (BCSC) on March 3, 2025, has been revoked. The revocation order was issued on March 20, 2025, following the Company’s filing of its audited annual financial statements for the year ended October 31, 2024, and other required documents on March 19, 2025.
The Company has also filed its interim financial statements for the three months ended January 31, 2025, and related filings as required by National Instrument 51-102 Continuous Disclosure Obligations. All filings are available on SEDAR+ at www.sedarplus.ca.
In a related announcement, BioVaxys has issued 1,200,000 common shares at a deemed value of $0.05 per share to settle $60,000 in debt owed to a lender. These securities are subject to a four-month statutory hold period from the date of issuance.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies based on its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform for treating cancers and infectious diseases. The Company’s clinical pipeline includes maveropepimut-S and BVX-0918, a personalized immunotherapeutic vaccine.
This news release includes forward-looking statements within the meaning of applicable securities legislation. These statements reflect the Company’s beliefs and projections based on current assumptions and estimates, which are subject to various uncertainties and contingencies.
The Canadian Securities Exchange has not reviewed or approved the contents of this press release.
